The liver is the body's primary site for estrogen processing. When it functions well, estrogens are broken down and excreted efficiently. When liver function is compromised — through fatty liver, inflammation, or nutritional deficiency — estrogen accumulates in circulation relative to progesterone.

This state, known as estrogen dominance, is linked to heavy periods, PMS, endometriosis, uterine fibroids, fibrocystic breasts, and increased risk of estrogen-sensitive cancers.

How the Liver Metabolises Estrogen

Hepatic estrogen clearance occurs in three stages.

Phase 1 — Hydroxylation. Liver CYP enzymes convert estradiol (E2) and estrone (E1) into hydroxylated intermediates.

Phase 2 — Conjugation. Hydroxylated metabolites are neutralised and made water-soluble via:

• Methylation (COMT enzyme, requires SAMe and magnesium)
• Glucuronidation (UGT enzymes) — the primary estradiol clearance route
• Sulfation (SULT enzymes)

Phase 3 — Gut Excretion. Conjugated estrogens enter bile and are eliminated in stool. However, gut bacteria producing beta-glucuronidase can deconjugate estrogen, allowing reabsorption into the bloodstream — a process called enterohepatic recirculation.

How Liver Dysfunction Disrupts Estrogen Balance

1. Reduced detoxification enzyme activity. NAFLD and liver inflammation decrease CYP enzyme and Phase 2 conjugation activity.

2. Low SHBG. Sex hormone-binding globulin (SHBG) is made exclusively in the liver. It binds estrogen in circulation, keeping it biologically inactive. Hepatic steatosis and insulin resistance reduces SHBG production, raising free estradiol levels independent of how much estrogen is actually produced.

3. Gut dysbiosis and the estrobolome. The estrobolome is the collection of gut bacteria capable of deconjugating estrogen. Dysbiosis — frequently seen alongside liver disease — increases beta-glucuronidase activity, amplifying enterohepatic recirculation and raising estrogen exposure.

4. Aromatase upregulation. Chronic liver inflammation elevates TNF-α and IL-6, which upregulate aromatase — the enzyme that converts androgens to estrogens in adipose tissue. Visceral fat becomes a significant estrogen source in metabolic disease.

5. Impaired COMT methylation. COMT inactivates potentially harmful catechol estrogen intermediates. This process requires SAMe, folate, B12, and magnesium — all depleted in liver disease. Reduced COMT activity allows accumulation of reactive intermediates with genotoxic potential.

Clinical Presentations

Impaired hepatic estrogen metabolism is associated with:

• Heavy or irregular menstrual bleeding
• PMS and PMDD
• Endometriosis
• Uterine fibroids
• PCOS (commonly co-exists with NAFLD)
• Fibrocystic breast changes
• Worsening insulin resistance and metabolic dysfunction

Evidence-Based Support Strategies

Cruciferous vegetables / I3C / DIM — modulate Phase 1 detoxification, shifting estrogen metabolism toward the protective 2-hydroxy pathway.

Methylation cofactors. Supporting COMT activity requires adequate folate (as 5-MTHF), methylcobalamin (B12), magnesium, and betaine. These are often depleted in both liver disease and estrogen-dominant conditions.

Reducing enterohepatic recirculation. Calcium D-glucarate inhibits intestinal beta-glucuronidase, reducing estrogen reabsorption. Dietary fibre binds conjugated estrogens in the gut, increasing faecal excretion. Regular bowel transit is essential — constipation directly increases estrogen reabsorption.

Limiting alcohol. Alcohol impairs Phase 1 and 2 detoxification, depletes NAD⁺, and upregulates adipose aromatase. Dose-dependent increases in circulating estradiol and estrone have been documented with even moderate alcohol consumption.

Insulin management. Elevated insulin suppresses SHBG transcription and activates aromatase. Low-glycaemic diets, reduced refined carbohydrates, and increased fibre all raise SHBG and lower free estradiol.

Liver-supportive compounds:

• Silymarin (milk thistle): protects hepatocytes and supports overall liver detoxification capacity, including Phase 2 conjugation and biliary excretion.
• N-acetyl cysteine (NAC): Replenishes hepatic glutathione, essential for Phase 2 detoxification.
• Artichoke leaf extract: Stimulates bile flow, the primary excretion route for conjugated estrogens.

Exercise. Regular physical activity reduces visceral adiposity, aromatase activity, and liver fat. Both aerobic and resistance training significantly reduce hepatic triglycerides in NAFLD.

References

• Abenavoli L, et al. Phytother Res. 2010;24(10):1423–1432.
• Aubertin-Leheudre M, Adlercreutz H. Br J Nutr. 2009.
• Barbagallo M, Dominguez LJ. World J Diabetes. 2015;6(10):1152–1157.
• Bertone-Johnson ER, et al. Arch Womens Ment Health. 2017;20(6):733–741.
• Bulun SE. N Engl J Med. 2009;360(3):268–279.
• Bulun SE, et al. Endocrinol Metab Clin North Am. 2021;50(1):125–139.
• Bulun SE, et al. Pharmacol Rev. 2005;57(3):359–383.
• Buzzard LM, et al. Clin Endocrinol (Oxf). 2020;93(3):235–249.
• Cavalieri E, Rogan E. J Steroid Biochem Mol Biol. 2011;125(3–5):169–180.
• Ding EL, et al. N Engl J Med. 2009;361(12):1152–1163.
• Dorgan JF, et al. Serum hormones and the alcohol–breast cancer association in postmenopausal women. J Natl Cancer Inst. 2001.
• Guillemette C. Pharmacogenomics J. 2003;3(3):136–158.
• Keating SE, et al. J Hepatol. 2012;57(1):157–166.
• Kwa M, et al. J Natl Cancer Inst. 2016;108(8):djw029.
• Lonardo A, et al. Hepatology. 2019;70(4):1457–1469.
• Mauvais-Jarvis F, et al. Endocr Rev. 2013;34(3):309–338.
• Melse-Boonstra A. Front Nutr. 2020;7:101.
• Merrell MD, Cherrington NJ. Drug Metab Rev. 2011;43(3):317–334.
• Mokhtari V, et al. Cell J. 2017;19(1):11–17.
• Palmery M, et al. Eur Rev Med Pharmacol Sci. 2013;17(13):1804–1813.
• Plottel CS, Blaser MJ. Cell Host Microbe. 2011;10(4):324–335.
• Reed MJ, et al. Endocr Rev. 2005;26(2):171–202.
• Simpson ER. J Steroid Biochem Mol Biol. 2003;86(3–5):225–230.
• Thomson CA, et al. Nutr Rev. 2016;74(7):432–443.
• Vargas-Mendoza N, et al. World J Hepatol. 2014;6(3):144–149.
• Wallace IR, et al. Clin Endocrinol. 2013;78(3):321–329.